‌

US Patent 12129309 Heterodimeric antibodies that bind CD3 and CD38

Patent 12129309 was granted and assigned to Xencor on October, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Matthew Bernett0

John Desjarlais0

Gregory Moore0

Umesh Muchhal0

Rumana Rashid0

Seung Chu0

Date of Patent

October 29, 2024

0

Patent Application Number

177364750

Date Filed

May 4, 2022

0

Patent Citations

US Patent 7276497 Cytotoxic agents comprising new maytansinoids

0

US Patent 7303749 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents

0

US Patent 7368565 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents

0

US Patent 6884869 Pentapeptide compounds and uses related thereto

0

US Patent 6989452 Disulfide prodrugs and linkers and stabilizers useful therefor

0

US Patent 7087600 Peptidyl prodrugs and linkers and stabilizers useful therefor

0

US Patent 7112324 CD 19×CD3 specific polypeptides and uses thereof

0

US Patent 7129261 Cytotoxic agents

0

...

Patent Primary Examiner

0

CPC Code

0

Patent abstract

The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12129309 Heterodimeric antibodies that bind CD3 and CD38

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.